ADC Therapeutics SA (ADCT) Reports Q2 Loss of $0.51/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- S&P 500 notches record-high close as rate-hike worries ease
- Oil settles down 2% on weak demand outlook, hefty US crude build
- BofA lifts server CPU TAM to $210bn+ on the rise of AI agents
- Burry doubles down on Nebius short after stock surges 34% on earnings
- JPMorgan gets bullish on Salesforce, says concerns are "overblown"
ADC Therapeutics Reports Second Quarter 2020 Financial Results and Provides Recent Business Highlights
August 18, 2020 7:15 AM EDT- On track to file BLA for Lonca for relapsed or refractory DLBCL later this year with commercial launch preparations ongoing
- Completed upsized $268 million initial public offering and received first tranche of $115 million Convertible Credit Facility from Deerfield
- Company to host conference call today at 8:30 a.m. EDT
LAUSANNE, Switzerland--(BUSINESS WIRE)-- ADC Therapeutics SA (NYSE: ADCT), a late clinical-stage oncology-focused biotechnology company pioneering the development and commercialization of highly potent and targeted antibody drug conjugates (ADCs) for patients with... More
